These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 32029622)

  • 1. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.
    Zhao P; Sun X; Chaggan C; Liao Z; In Wong K; He F; Singh S; Loomba R; Karin M; Witztum JL; Saltiel AR
    Science; 2020 Feb; 367(6478):652-660. PubMed ID: 32029622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.
    Zhao P; Saltiel AR
    J Biol Chem; 2020 Aug; 295(34):12279-12289. PubMed ID: 32651233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTZ attenuates liver steatosis and fibrosis in the minipigs with type 2 diabetes by regulating the AMPK signaling pathway.
    Wang H; Huang M; Bei W; Yang Y; Song L; Zhang D; Zhan W; Zhang Y; Chen X; Wang W; Wang L; Guo J
    Biomed Pharmacother; 2021 Jun; 138():111532. PubMed ID: 34311531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
    Gluais-Dagorn P; Foretz M; Steinberg GR; Batchuluun B; Zawistowska-Deniziak A; Lambooij JM; Guigas B; Carling D; Monternier PA; Moller DE; Bolze S; Hallakou-Bozec S
    Hepatol Commun; 2022 Jan; 6(1):101-119. PubMed ID: 34494384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models.
    Esquejo RM; Salatto CT; Delmore J; Albuquerque B; Reyes A; Shi Y; Moccia R; Cokorinos E; Peloquin M; Monetti M; Barricklow J; Bollinger E; Smith BK; Day EA; Nguyen C; Geoghegan KF; Kreeger JM; Opsahl A; Ward J; Kalgutkar AS; Tess D; Butler L; Shirai N; Osborne TF; Steinberg GR; Birnbaum MJ; Cameron KO; Miller RA
    EBioMedicine; 2018 May; 31():122-132. PubMed ID: 29673898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.
    Lan T; Yu Y; Zhang J; Li H; Weng Q; Jiang S; Tian S; Xu T; Hu S; Yang G; Zhang Y; Wang W; Wang L; Zhu Q; Rong X; Guo J
    Hepatology; 2021 Aug; 74(2):686-703. PubMed ID: 33576035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspase-11-Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic Steatohepatitis.
    Zhu Y; Zhao H; Lu J; Lin K; Ni J; Wu G; Tang H
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):653-664. PubMed ID: 33894425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy.
    Jin X; Gao J; Zheng R; Yu M; Ren Y; Yan T; Huang Y; Li Y
    Cell Death Dis; 2020 Feb; 11(2):123. PubMed ID: 32054840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
    Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes.
    Tanaka M; Sato A; Kishimoto Y; Mabashi-Asazuma H; Kondo K; Iida K
    Nutrients; 2020 May; 12(5):. PubMed ID: 32443660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salsalate reverses metabolic disorders in a mouse model of non-alcoholic fatty liver disease through AMPK activation and caspase-6 activity inhibition.
    Li J; Chen C; Zhang W; Bi J; Yang G; Li E
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):394-409. PubMed ID: 33200549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.
    Zhang X; Liu S; Zhang C; Zhang S; Yue Y; Zhang Y; Chen L; Yao Z; Niu W
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165854. PubMed ID: 32502647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
    Lin Q; Huang Z; Cai G; Fan X; Yan X; Liu Z; Zhao Z; Li J; Li J; Shi H; Kong M; Zheng MH; Conklin DJ; Epstein PN; Wintergerst KA; Mohammadi M; Cai L; Li X; Li Y; Tan Y
    Hepatology; 2021 Jun; 73(6):2206-2222. PubMed ID: 32965675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
    Komiya C; Tanaka M; Tsuchiya K; Shimazu N; Mori K; Furuke S; Miyachi Y; Shiba K; Yamaguchi S; Ikeda K; Ochi K; Nakabayashi K; Hata KI; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2017 Mar; 7():44754. PubMed ID: 28303974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of nonalcoholic fatty liver disease: role of AMPK.
    Smith BK; Marcinko K; Desjardins EM; Lally JS; Ford RJ; Steinberg GR
    Am J Physiol Endocrinol Metab; 2016 Oct; 311(4):E730-E740. PubMed ID: 27577854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice.
    Hu M; Zhang D; Xu H; Zhang Y; Shi H; Huang X; Wang X; Wu Y; Qi Z
    Hepatology; 2021 Dec; 74(6):3056-3073. PubMed ID: 34292604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
    Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
    Song L; Wang L; Hou Y; Zhou J; Chen C; Ye X; Dong W; Gao H; Liu Y; Qiao G; Pan T; Chen Q; Cao Y; Hu F; Rao Z; Chen Y; Han Y; Zheng M; Luo Y; Li X; Chen Y; Huang Z
    Hepatology; 2022 Oct; 76(4):1105-1120. PubMed ID: 35152446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Wan J; Zhang Y; Yang D; Liang Y; Yang L; Hu S; Liu Z; Fang Q; Tian S; Ding Y
    Hepatology; 2021 Dec; 74(6):3074-3090. PubMed ID: 34297426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.